Mylan’s Generic Version of Biogen’s MS Drug Gets FDA Approval Post author:Sam Post published:August 20, 2020 Post category:Devices & Diagnostics Letter Mylan has launched the product in 120mg and 240mg delayed-release capsule forms. Source: Devices & Diagnostics Letter You Might Also Like Keytruda Approved in China for Esophageal Squamous Cell Carcinoma June 22, 2020 Indianapolis Helmet Maker Warned on Records, Procedural Flaws April 7, 2016 HHS Says Memo Won’t Take Power From the FDA September 20, 2020